Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





CDC Releases Consolidated Recommendations for COVID-19 Testing

By LabMedica International staff writers
Posted on 19 Jun 2020
The Centers for Disease Control and Prevention (CDC Atlanta, GA, USA) has released consolidated recommendations for COVID-19 testing, including interim testing guidelines for nursing home residents and healthcare personnel.

These recommendations which compile and update previous testing guidance also include testing strategy options for high-density critical infrastructure workplaces after a COVID-19 case is identified. More...
The consolidated recommendations for testing, Overview of Testing for SARS-CoV-2, have been developed based on what is currently known about COVID-19 and are subject to be changed by the CDC as additional information becomes available.

The current CDC recommendations are for testing people who have signs or symptoms of COVID-19; have no symptoms but recently had contact with someone known or suspected to have COVID-19; have no symptoms and no known contact with someone known or suspected to have COVID-19 but still may be tested for early identification in special settings; have had confirmed COVID-19 but no longer have symptoms; and may be tested by public health officials to track spread of the virus that causes COVID-19.

Testing Guidelines for Nursing Homes is an important addition to other infection prevention and control (IPC) recommendations aimed at keeping COVID-19 out of nursing homes (as well as other long-term care facilities), detecting cases quickly if they do occur, and stopping further transmission in these facilities. The CDC’s updated recommendations include recommendation against testing the same individual more than once in a 24-hour period; consideration for testing residents with symptoms for other causes of respiratory illness, such as influenza; and coordination of repeat testing in response to outbreaks with local, territorial, and state health departments.

The CDC has also recommended that appropriate workplace protections, such as engineering and administrative controls, for those present in the workplace should remain in place. Additionally, the CDC’s Testing Strategy for Coronavirus (COVID-19) in High-Density Critical Infrastructure Workplaces after a COVID-19 Case is Identified presents different testing strategy options for exposed co-workers when public health organizations and employers determine testing is needed to help support existing disease control measures. Such strategies can aid in identifying infectious individuals with the goal of reducing transmission of SARS-CoV-2 in the workplace.

Related Links:
The Centers for Disease Control and Prevention (CDC)


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.